Krka Enjoys ‘Strongest’ Half Year, Although Prescription Stagnates

Having picked up five prescription marketing authorization approvals in the first half of 2021, Slovenian generics giant Krka will be hoping to build on stagnant prescription pharmaceuticals reported in preliminary financial results.